Marika Ciprotti

680 total citations
17 papers, 423 citations indexed

About

Marika Ciprotti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marika Ciprotti has authored 17 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marika Ciprotti's work include Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Marika Ciprotti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Marika Ciprotti collaborates with scholars based in United States, France and United Kingdom. Marika Ciprotti's co-authors include Karim Fizazi, Russell K. Pachynski, Sumit K. Subudhi, Vivek Narayan, Yanhua Hu, Akash Patnaik, Gwénaëlle Gravis, Padmanee Sharma, Abdel Saci and Aude Fléchon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Annals of Oncology.

In The Last Decade

Marika Ciprotti

16 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marika Ciprotti United States	7	303	255	159	62	59	17	423
Maria Anderson United States	8	349 1.2×	115 0.5×	175 1.1×	82 1.3×	38 0.6×	10	423
Bhumsuk Keam South Korea	9	312 1.0×	134 0.5×	122 0.8×	98 1.6×	56 0.9×	17	568
Andrej Valkov Norway	13	247 0.8×	231 0.9×	113 0.7×	105 1.7×	81 1.4×	14	406
Go Oshima United States	7	181 0.6×	174 0.7×	68 0.4×	113 1.8×	146 2.5×	13	418
Jayne S. Gurtler United States	7	653 2.2×	260 1.0×	262 1.6×	92 1.5×	131 2.2×	10	743
Elaine Shum United States	13	388 1.3×	348 1.4×	78 0.5×	176 2.8×	69 1.2×	52	586
Jessica Salvini Italy	3	460 1.5×	339 1.3×	96 0.6×	93 1.5×	90 1.5×	4	551
Ruslan D. Novosiadly United States	9	346 1.1×	114 0.4×	155 1.0×	207 3.3×	114 1.9×	22	540
Yujun Park South Korea	11	226 0.7×	114 0.4×	86 0.5×	60 1.0×	53 0.9×	19	332
Bruce McCall United States	10	276 0.9×	103 0.4×	95 0.6×	108 1.7×	26 0.4×	14	376

Countries citing papers authored by Marika Ciprotti

Since Specialization

Citations

This map shows the geographic impact of Marika Ciprotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marika Ciprotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marika Ciprotti more than expected).

Fields of papers citing papers by Marika Ciprotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marika Ciprotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marika Ciprotti. The network helps show where Marika Ciprotti may publish in the future.

Co-authorship network of co-authors of Marika Ciprotti

This figure shows the co-authorship network connecting the top 25 collaborators of Marika Ciprotti. A scholar is included among the top collaborators of Marika Ciprotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marika Ciprotti. Marika Ciprotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sandler, Howard M., Stephen J. Freedland, Neal D. Shore, et al.. (2022). Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).. Journal of Clinical Oncology. 40(16_suppl). 5084–5084. 5 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations

Sharma, Padmanee, Russell K. Pachynski, Vivek Narayan, et al.. (2020). Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 38(4). 489–499.e3. 257 indexed citations

Drake, Charles G., Fred Saad, William R. Clark, et al.. (2020). 690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX). Annals of Oncology. 31. S546–S546. 6 indexed citations

Sharma, Padmanee, Russell K. Pachynski, Vivek Narayan, et al.. (2019). Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).. Journal of Clinical Oncology. 37(7_suppl). 142–142. 70 indexed citations

Fizazi, Karim, Daniel Castellano, Arash Rezazadeh Kalebasty, et al.. (2019). Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD. Annals of Oncology. 30. v885–v886. 10 indexed citations

Fizazi, Karim, Charles G. Drake, David R. Shaffer, et al.. (2018). An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).. Journal of Clinical Oncology. 36(15_suppl). TPS3126–TPS3126. 5 indexed citations

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations

Kelly, Ronan J., A. Craig Lockhart, Derek J. Jonker, et al.. (2017). CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology. 35(4_suppl). TPS212–TPS212. 15 indexed citations

10.

Kelly, Ronan J., A. Craig Lockhart, Derek J. Jonker, et al.. (2017). CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS4131–TPS4131. 5 indexed citations

11.

Ciprotti, Marika, Reimar Abraham, Mendel Jansen, et al.. (2016). A phase I, open label, two part, safety and tolerability study of U3-1784 in patients with advanced solid tumours.. Journal of Clinical Oncology. 34(15_suppl). TPS2593–TPS2593. 2 indexed citations

12.

Ciprotti, Marika, Geoffrey Chong, Hui Gan, et al.. (2014). Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma. EJNMMI Research. 4(1). 22–22. 9 indexed citations

13.

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2013). A phase I and biodistribution study of ABT-806i, an ¹¹¹indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.. Journal of Clinical Oncology. 31(15_suppl). 2520–2520. 15 indexed citations

14.

Masi, Gianluca, Fotios Loupakis, Giacomo Giulio Baldi, et al.. (2008). First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group. CINECA IRIS Institutial research information system (University of Pisa). 2 indexed citations

15.

Masi, Gianluca, Fotios Loupakis, Enrico Vasile, et al.. (2008). Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab. CINECA IRIS Institutial research information system (University of Pisa). 3 indexed citations

16.

D’Auria, Giuliana, Marika Ciprotti, D. Conte, et al.. (2007). Neo-adjuvant and adjuvant chemotherapy in bladder cancer. Annals of Oncology. 18. vi162–vi163. 1 indexed citations

17.

Ferraldeschi, Roberta, et al.. (2005). Induction therapy before surgery for non-small cell lung cancer.. PubMed. 29(4). 445–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact